Skip to main
ETON

ETON Stock Forecast & Price Target

ETON Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Eton Pharmaceuticals is a specialty pharmaceutical company with a strong portfolio of rare disease products and a promising pipeline of late-stage candidates. The company has a history of successful drug launches and a targeted approach to strategic acquisitions, positioning them for continued growth and potential outperformance in the pharmaceutical market. Additionally, management's execution to date and their stated long-term goals suggest potential for strong financial performance and value creation for shareholders.

Bears say

Eton Pharmaceuticals is set to experience growth with their exclusive rights to market the FDA-approved oral therapy for leishmaniasis, with a projected $200M annual revenue by 2027. Their current revenue base of $8M and a discounted net present value of $1.58B supports a buy rating and 12-month price target of $57.00 per diluted share. Risks may arise in the areas of clinical, commercial, collaboration, dilution, legal and intellectual property, and competition.

ETON has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Eton Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Eton Pharmaceuticals Inc (ETON) Forecast

Analysts have given ETON a Strong Buy based on their latest research and market trends.

According to 4 analysts, ETON has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $54.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $54.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Eton Pharmaceuticals Inc (ETON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.